Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Medtronic

Medtronic offers medical products and therapies for the treatment of cardiac and vascular diseases, diabetes, and neu... read more Featured Products: More products

Download Mobile App




Neurostimulation Device Helps Treat Intractable Gastroparesis

By HospiMedica International staff writers
Posted on 03 Feb 2015
An improved neurostimulation system treats chronic, drug-refractory nausea and vomiting associated with gastroparesis of diabetic or unknown origin.

The Medtronic Enterra II System consists of a small neurostimulator implanted under the skin, usually in the lower abdominal region. More...
Two insulated leads are implanted into the stomach wall muscle and connected to the neurostimulator, which then delivers mild electrical pulses to stimulate the smooth muscles of the lower stomach. After the device is implanted, a handheld external programmer is used to noninvasively adjust the neurostimulator and customize the stimulation to each patient's needs.

While the Enterra Therapy has been available to patients since 2000, the new Enterra II System improves the therapy by providing physicians with greater system flexibility and ease of use. The Enterra II features improved programming software, improvements to the system's battery-life indicator, and a customized tool that simplifies implantation of the device for physicians. The Enterra II System is a product of Medtronic (Minneapolis, MN, USA), and has been approved by the US Food and Drug Administration (FDA), under a humanitarian device exemption (HDE).

“Medtronic Enterra Therapy is a well-established treatment option, and we are pleased to make the new Enterra II System available to physicians and patients,” said Linnea Burman, vice president and general manager of gastro/urology therapies at Medtronic. “These therapy enhancements are the latest examples of our ongoing commitment to provide physicians with a therapy that eases life-altering gastroparesis symptoms and enables patients to more comfortably participate in the things they enjoy.”

“Enterra Therapy is an important option for people suffering from the severe effects of gastroparesis, including chronic nausea and vomiting,” said Prof. Henry Parkman, MD, of Temple University (Philadelphia, PA, USA) and director of the GI motility laboratory at Temple University Hospital. “The new advanced system simplifies the implantation process and is easy to program.”

Gastroparesis, also called delayed gastric emptying, is a condition resulting from a partial paralysis of the stomach. This causes the muscles of the stomach and intestines to not properly function; food then moves slowly or not at all through the digestive tract. The condition may occur when the vagus nerve is damaged, but has a number of potential causes, and is particularly associated with diabetes. The condition occurs in about 5% of the diabetic population.

Related Links:

Medtronic



Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Mobile X-Ray System
K4W
Radiation Safety Barrier
RayShield Intensi-Barrier
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.